Ajooni Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

Revenue Growth 20pctPat Growth 25pctEbitda Margin CompressionRelated Party TransactionsResults View source PDF

AJOONI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-5.4%1-day move

₹4.27

prior close

₹4.25

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-1.2-0.9-0.7-0.9-5.4-4.7-6.3-7.5-8.4-7.7-11.2-14.1——

Up moveDown movePending

AI summary

Ajooni Biotech Limited reported strong revenue growth with total income of Rs. 18,479.62 Lakhs for FY 2025-26, up 58% from Rs. 11,676.09 Lakhs in the previous year. Revenue from operations grew to Rs. 18,237.81 Lakhs from Rs. 11,469.19 Lakhs. Net profit improved to Rs. 432.19 Lakhs versus Rs. 337.20 Lakhs, representing a 28% increase. The auditors issued an unmodified opinion with no qualifications. A clean audit opinion was declared. The company has disclosed related party transactions with Khanna Solvex, a partnership firm where Managing Director Jasjot Singh is a partner, providing security for HDFC Bank loans. Cash and cash equivalents declined significantly from Rs. 683.02 Lakhs to Rs. 41.90 Lakhs.

Likely market impact

The company showed robust top-line and bottom-line growth with a clean audit, which is positive for shareholders. However, the significant decline in cash reserves and related party transactions involving the MD warrant monitoring.